Belgium's Solvay said it should have more clarity on the future of its pharmaceuticals unit in the fourth quarter. All options, including keeping the unit as-is, are still on the table, CEO Christian Jourquin said. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments